Phase III Mariposa study evaluating Rybrevant + lazertinib meets primary endpoint in PFS in NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III MARIPOSA study met is primary endpoint resulting in statistically significant and clinically meaningful improvement in progression-free survival for Rybrevant (amivantamab-vmjw) plus lazertinib versus osimertinib in patients with EGFR-Mutated non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA issued a Complete Response Letter to Summit Therapeutics Inc. regarding the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody.
FDA granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login